Study of ISIS 703802 in Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Details

Instance of

clinical trial

Start time

18 December 2017

End time

28 February 2019

Country

Canada, United States

Main subject

fatty liver disease, hypertriglyceridemia, diabetes, metabolic dysfunction–associated steatotic liver disease

clinical trial phase

phase II clinical trial

maximum age

70

minimum age

18

number of participants

144

study type

interventional study

title

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)